Historically, the FDA has required drug discovery and development programs to include animal testing. With the 2022 passage of the FDA Modernization Act 2.0, the definition of “nonclinical tests” conducted to support pharmaceutical development has been broadened to include adjunct and complementary testing methods.
In this webinar with Certara’s Dr. Jim Herman, he will discuss how scientists can use innovative, leading-edge technologies more fully in future drug discovery and development strategies.
By attending this interactive webinar, you will learn:
• How this change can facilitate expanded use of alternatives to animal testing including biosimulation, organ-on-a-chip, and cell-based assays.
• Best practices in toxicology to streamline non-clinical development and
assessment of drug safety
• The coming trends in the pharmaceutical industry to support the 3Rs of animal testing (reduce, refine, replace)
